FAQ • Register (In-Person or Virtual!) • Schedule • Posters • Engage/Mentoring • Students • Destination • Supporters • Planning Committee • AAPP at Work

Clinical Pearls

Registration Options

Activity Date: 04/18/2023

Sign in (or create a FREE account) to register or access your existing registrations

Session Time and Location

The live session is complete.

Target Audience

If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.

Session Summary

Clinical Pearls presentations will be recorded and posted but are only available for live credit.

Clozapine-Induced Gastrointestinal Hypomotility
Katie S. Adams, PharmD, BCPS, BCPP

Clozapine-induced gastrointestinal hypomotility (CIGH) is a well-documented but under-recognized adverse effect that is associated with higher mortality than agranulocytosis. Despite this, it has only recently been recognized by the FDA with an updated warning in the package labeling. There is a lack of data specific to medication management, preventative strategies, or recommendations on how to re-challenge patients after a serious CIGH related outcome. This clinical pearl explores the available evidence for CIGH and its application to a patient case.

Aripiprazole for Anorexia Nervosa
Danielle Stutzman, PharmD, BCPP

Pharmacologic treatment options are limited in Anorexia Nervosa. While atypical antipsychotics have been evaluated for targeting cognitive distortions regarding food/body image/weight gain and severe obsessional thinking, current treatment options are limited by adverse effects and lack of robust evidence for use. This clinical pearl will review current evidence and discuss the potential role of aripiprazole in clinical practice for treating Anorexia Nervosa.

Xylazine: A New Deadly Threat to Public Health
Katie Liveoak, PharmD, BCPP

Xylazine is a tranquilizer commonly added into the illicit drug supply, predominantly seen as an adulterant in substances such as cocaine, heroin, and illicitly manufactured fentanyl. It is a likely contributor to overdoses because it does not respond to naloxone reversal. Recent publications indicate a trend of increasing xylazine detection in seized drug samples, toxicity cases, and overdose deaths. The Food and Drug Administration issued a warning in November 2022 providing clinical information about the risks of severe, necrotic skin ulcerations from repeated xylazine exposure, possible withdrawal symptoms, and xylazine’s interference with successful treatment of opioid overdoses. This clinical pearl will provide an overview of xylazine, including risks associated with exposure and overdose mitigation strategies.

Course Requirements

To receive ACPE credit for the live session at the Annual Meeting, you must:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Attend and participate in the entire session and reflect upon its teachings.
  • Complete the evaluation at the end of the activity.
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information

Katie S. Adams, PharmD, BCPS, BCPP
Danielle Stutzman, PharmD, BCPP
Katie Liveoak, PharmD, BCPP

View biographical information

Learning Objectives

Clozapine-Induced Gastrointestinal Hypomotility

  1. Review the receptor binding profile and corresponding pharmacodynamics effect of clozapine on the gastrointestinal (GI) tract.
  2. Evaluate available evidence for management of clozapine-induced gastrointestinal hypomotility (CIGH).

Aripiprazole for Anorexia Nervosa

  1. Describe standard psychotropic treatment approach in individuals with anorexia nervosa.
  2. Interpret available literature surrounding aripiprazole use in anorexia nervosa.
  3. Identify patient-specific factors that may warrant a trial of aripiprazole. 

Xylazine: A New Deadly Threat to Public Health

  1. Recognize clinical presentation and risks associated with xylazine exposure.
  2. Identify barriers to identification and appropriate treatment for xylazine exposure.
  3. List overdose mitigation strategies for xylazine.

Continuing Education Credit and Disclosures

Activity Date: 04/18/2023
ACPE Contact Hours: 1
ACPE Number: 0284-0000-23-038-L01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.